The Evolving World of GLP-1 Agonist Therapies for Type 2 Diabetes

Overview

Journal Ther Adv Endocrinol Metab

Specialty Endocrinology

Date 2012 Nov 14

PMID 23148151

Citations 3

Authors

Kevin C R Baynes

Affiliations

Soon will be listed here.

Abstract

The glucagon-like peptide-1 (GLP-1) agonist drugs have attractions as a treatment for type 2 diabetes since they positively alter a number of key pathophysiological defects. These include increasing insulin release, reducing glucagon release, slowing gastric emptying and reducing food intake. In numerous clinical trials these agents have been shown to reduce DCCT-aligned HbA(1c) between 0.8% and 1.1% in patients with moderately controlled type 2 diabetes, whilst also being associated with some weight loss. Whilst medium-term safety and side-effect profiles are now well established, there are as yet no long-term studies on the safety of this group of drugs. The place of the GLP-1 agonists in the treatment paradigm for type 2 diabetes will evolve over the next decade.

Citing Articles

What kind of illness is anorexia nervosa? Revisited: some preliminary thoughts to finding a cure.

Touyz S, Bryant E, Dann K, Polivy J, Le Grange D, Hay P J Eat Disord. 2023; 11(1):221.

PMID: 38082362 PMC: 10714619. DOI: 10.1186/s40337-023-00944-3.

Insulin Initiation and Titration in Patients With Type 2 Diabetes.

Chun J, Strong J, Urquhart S Diabetes Spectr. 2019; 32(2):104-111.

PMID: 31168280 PMC: 6528396. DOI: 10.2337/ds18-0005.

G protein-coupled receptors as targets for anti-diabetic therapeutics.

Oh D, Olefsky J Nat Rev Drug Discov. 2016; 15(3):161-72.

PMID: 26822831 DOI: 10.1038/nrd.2015.4.

References

Nauck M, Duran S, Kim D, Johns D, Northrup J, Festa A . A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia. 2006; 50(2):259-67. DOI: 10.1007/s00125-006-0510-2. View

Russell-Jones D, Vaag A, Schmitz O, Sethi B, Lalic N, Antic S . Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia. 2009; 52(10):2046-55. PMC: 2744824. DOI: 10.1007/s00125-009-1472-y. View

Raman V, Mason K, Rodriguez L, Hassan K, Yu X, Bomgaars L . The role of adjunctive exenatide therapy in pediatric type 1 diabetes. Diabetes Care. 2010; 33(6):1294-6. PMC: 2875441. DOI: 10.2337/dc09-1959. View

Sourij H, Schmolzer I, Kettler-Schmut E, Eder M, Pressl H, Decampo A . Efficacy of a continuous GLP-1 infusion compared with a structured insulin infusion protocol to reach normoglycemia in nonfasted type 2 diabetic patients: a clinical pilot trial. Diabetes Care. 2009; 32(9):1669-71. PMC: 2732139. DOI: 10.2337/dc09-0475. View

Zinman B, Hoogwerf B, Garcia S, Milton D, Giaconia J, Kim D . The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med. 2007; 146(7):477-85. DOI: 10.7326/0003-4819-146-7-200704030-00003. View

Marre M, Shaw J, Brandle M, Bebakar W, Kamaruddin N, Strand J . Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabet Med. 2009; 26(3):268-78. PMC: 2871176. DOI: 10.1111/j.1464-5491.2009.02666.x. View

Brubaker P . Minireview: update on incretin biology: focus on glucagon-like peptide-1. Endocrinology. 2010; 151(5):1984-9. DOI: 10.1210/en.2010-0115. View

Heine R, Van Gaal L, Johns D, Mihm M, Widel M, Brodows R . Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med. 2005; 143(8):559-69. DOI: 10.7326/0003-4819-143-8-200510180-00006. View

Rachman J, Barrow B, Levy J, Turner R . Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM. Diabetologia. 1997; 40(2):205-11. DOI: 10.1007/s001250050664. View

10.

Smith U, Gale E . Does diabetes therapy influence the risk of cancer?. Diabetologia. 2009; 52(9):1699-708. DOI: 10.1007/s00125-009-1441-5. View

11.

Yoon N, Cavaghan M, Brunelle R, Roach P . Exenatide added to insulin therapy: a retrospective review of clinical practice over two years in an academic endocrinology outpatient setting. Clin Ther. 2009; 31(7):1511-23. DOI: 10.1016/j.clinthera.2009.07.021. View

12.

le Roux C, Aylwin S, Batterham R, Borg C, Coyle F, Prasad V . Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters. Ann Surg. 2005; 243(1):108-14. PMC: 1449984. DOI: 10.1097/01.sla.0000183349.16877.84. View

13.

Chia C, Carlson O, Kim W, Shin Y, Charles C, Kim H . Exogenous glucose-dependent insulinotropic polypeptide worsens post prandial hyperglycemia in type 2 diabetes. Diabetes. 2009; 58(6):1342-9. PMC: 2682676. DOI: 10.2337/db08-0958. View

14.

Kendall D, Riddle M, Rosenstock J, Zhuang D, Kim D, Fineman M . Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care. 2005; 28(5):1083-91. DOI: 10.2337/diacare.28.5.1083. View

15.

Garber A, Henry R, Ratner R, Garcia-Hernandez P, Rodriguez-Pattzi H, Olvera-Alvarez I . Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet. 2008; 373(9662):473-81. DOI: 10.1016/S0140-6736(08)61246-5. View

16.

Buse J, Henry R, Han J, Kim D, Fineman M, Baron A . Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care. 2004; 27(11):2628-35. DOI: 10.2337/diacare.27.11.2628. View

17.

Ratner R, Maggs D, Nielsen L, Stonehouse A, Poon T, Zhang B . Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2006; 8(4):419-28. DOI: 10.1111/j.1463-1326.2006.00589.x. View

18.

Froud T, Faradji R, Pileggi A, Messinger S, Baidal D, Ponte G . The use of exenatide in islet transplant recipients with chronic allograft dysfunction: safety, efficacy, and metabolic effects. Transplantation. 2008; 86(1):36-45. PMC: 2772201. DOI: 10.1097/TP.0b013e31817c4ab3. View

19.

Drucker D . The biology of incretin hormones. Cell Metab. 2006; 3(3):153-65. DOI: 10.1016/j.cmet.2006.01.004. View

20.

Ahmad S, Swann J . Exenatide and rare adverse events. N Engl J Med. 2008; 358(18):1970-1. View